Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
- Author(s)
- Loong, HH; Shimizu, T; Prawira, A; Tan, AC; Tran, B; Day, D; Tan, DSP; Ting, FIL; Chiu, JW; Hui, M; Wilson, MK; Prasongsook, N; Koyama, T; Reungwetwattana, T; Tan, TJ; Heong, V; Voon, PJ; Park, S; Tan, IB; Chan, SL; Tan, DSW;
- Details
- Publication Year 2023-06-23,Volume 8,Issue #4,Page 101586
- Journal Title
- ESMO Open
- Publication Type
- Review
- Abstract
- INTRODUCTION: Next-generation sequencing (NGS) diagnostics have shown clinical utility in predicting survival benefits in patients with certain cancer types who are undergoing targeted drug therapies. Currently, there are no guidelines or recommendations for the use of NGS in patients with metastatic cancer from an Asian perspective. In this article, we present the Asia-Pacific Oncology Drug Development Consortium (APODDC) recommendations for the clinical use of NGS in metastatic cancers. METHODS: The APODDC set up a group of experts in the field of clinical cancer genomics to (i) understand the current NGS landscape for metastatic cancers in the Asia-Pacific (APAC) region; (ii) discuss key challenges in the adoption of NGS testing in clinical practice; and (iii) adapt/modify the European Society for Medical Oncology guidelines for local use. Nine cancer types [breast cancer (BC), gastric cancer (GC), nasopharyngeal cancer (NPC), ovarian cancer (OC), prostate cancer, lung cancer, and colorectal cancer (CRC) as well as cholangiocarcinoma and hepatocellular carcinoma (HCC)] were identified, and the applicability of NGS was evaluated in daily practice and/or clinical research. Asian ethnicity, accessibility of NGS testing, reimbursement, and socioeconomic and local practice characteristics were taken into consideration. RESULTS: The APODDC recommends NGS testing in metastatic non-small-cell lung cancer (NSCLC). Routine NGS testing is not recommended in metastatic BC, GC, and NPC as well as cholangiocarcinoma and HCC. The group suggested that patients with epithelial OC may be offered germline and/or somatic genetic testing for BReast CAncer gene 1 (BRCA1), BRCA2, and other OC susceptibility genes. Access to poly (ADP-ribose) polymerase inhibitors is required for NGS to be of clinical utility in prostate cancer. Allele-specific PCR or a small-panel multiplex-gene NGS was suggested to identify key alterations in CRC. CONCLUSION: This document offers practical guidance on the clinical utility of NGS in specific cancer indications from an Asian perspective.
- Publisher
- Elsevier
- Keywords
- Asia-Pacific; genomic alterations; metastatic cancers; next-generation sequencing
- Department(s)
- Medical Oncology
- PubMed ID
- 37356359
- Publisher's Version
- https://doi.org/10.1016/j.esmoop.2023.101586
- Open Access at Publisher's Site
https://doi.org/10.1016/j.esmoop.2023.101586- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-10-03 06:40:01
Last Modified: 2023-10-04 12:44:04